title: [Therapeutic antibodies and related products: choosing the right structure for success].
abstract: Monoclonal antibodies (mAb) and related-products represent the fastest growing class of therapeutics in the biotechnological and pharmaceutical industry. In just as short as 20 years, more than 30 immunoglobulins (IgG) and derivatives have been approved in a wide range of indications (oncology, inflammation and auto-immunity, transplantation, angioplasty, hematology, ophthalmology, viral infections, allergy). The mAb structure toolbox contains mouse, chimeric, humanized and human antibodies from different isotypes (IgG1, 2 and 4), as well as IgG-related products (immunoconjugates, radio-immunoconjugates, Fab fragments, Fc-fusion proteins and peptides, bispecifics). Furthermore from a structural point of view, mAb glycosylation is linked to their production systems and may impact on their effector functions and immunogenicity. Based on the current knowledge, choosing the right antibody format, isotype and glycosylation profile are some of the key issues to address early during the lead selection.
authors.affiliation: Centre d'immunologie Pierre Fabre (www.cipf.com), 5, avenue Napoléon III, 74160 Saint-Julien-en-Genevois, France. alain.beck@pierre-fabre.com
authors.forename: Alain
authors.initials: A
authors.lastname: Beck
authors.forename: Elsa
authors.initials: E
authors.lastname: Wagner-Rousset
authors.forename: Thierry
authors.initials: T
authors.lastname: Wurch
authors.forename: Nathalie
authors.initials: N
authors.lastname: Corvaia
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use*; D000916:Antibody Diversity; D016503:Drug Delivery Systems; D006031:Glycosylation; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007128:Immunoglobulin Fragments / Q000737:chemistry / Q000276:immunology; D007074:Immunoglobulin G / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use; D051379:Mice; D011487:Protein Conformation; D015202:Protein Engineering; D011499:Protein Processing, Post-Translational; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000627:therapeutic use; D013045:Species Specificity; D013329:Structure-Activity Relationship
chemical_list: D000911:Antibodies, Monoclonal; D018796:Immunoconjugates; D007128:Immunoglobulin Fragments; D007074:Immunoglobulin G; D011993:Recombinant Fusion Proteins